Anaconda Biomed, a medical technology company with operations in Barcelona and Marin, California, announced the closing of a $56 million financing round on September 23, 2026. The company is developing a next-generation portfolio of thrombectomy catheters based on its core funnel catheter technology platform. The new capital will support clinical development, product advancement, and global regulatory efforts for its neurovascular devices.
Investor Syndicate and Use of Proceeds
The financing was led by Omega Funds and included new investor Spain's Co-investment fund, FOCO, which is managed by COFIDES. Existing investors Asabys through Sabadell Asabys II, Ysios Capital, and CDTI through its SICC Innvierte also participated in the round. Proceeds are designated to complete the ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for the neurovascular portfolio.
Clinical and Regulatory Milestones
The ATHENA pivotal IDE study is a prospective, randomized, 327-subject trial designed to evaluate the safety and performance of the ANA Funnel Catheter. Completing this study is a central priority for Anaconda as it builds clinical evidence for its technology. The funding ensures the company has the resources needed to meet clinical and regulatory requirements in key markets.
Funnel Catheter Technology
Anaconda's proprietary Funnel Catheter platform is an endovascular technology intended to improve clot capture, reduce embolic complications, and maximize brain reperfusion. It combines aspiration power with flow-arrest and flow-reversal to address clot retrieval, fragmentation, and downstream embolization. The broader product portfolio will include complementary tools such as stent retrievers, sheaths, and guidewires for additional clinical applications.
Executive Perspectives
Chief Executive Officer Trent Reutiman said the latest funding allows the company to further advance acute stroke treatment and reduce disability and death caused by large vessel occlusive disease. He added that the investor group's support reflects growing confidence in the technology platform and provides the resources required for clinical and regulatory work. Claudio Nessi, Managing Director of Omega Funds, noted that Anaconda is bringing a next-generation solution to the large ischemic stroke market.
Market Need and Stroke Burden
Strokes cause approximately seven million deaths each year, with ischemic strokes accounting for about 65 percent of cases. Mechanical thrombectomy is used in roughly 30 percent of these ischemic stroke patients. An estimated 270,000 mechanical thrombectomy procedures will be performed globally in 2026, representing only a fraction of the total addressable market.
Growing Market Opportunity
The global mechanical thrombectomy market remains significantly underpenetrated relative to the number of eligible stroke patients. Anaconda is targeting this gap with a platform designed to improve procedural efficiency and patient outcomes. The company believes its technology can help expand access to effective stroke intervention across a broader patient population.
Manufacturing and Strategic Position
Anaconda has established a state-of-the-art production facility on the edge of Barcelona to support its development and manufacturing activities. Direct control over key processes enables nimble, efficient, and iterative product expansion. The company is also building meaningful manufacturing trade secrets associated with its core technology, strengthening its long-term competitive position.
With $56 million in new financing, Anaconda Biomed is positioned to advance its clinical trial, expand its product portfolio, and pursue regulatory approvals in the interventional neurovascular device market. The participation of both new and existing investors highlights continued confidence in the company's funnel catheter platform. By targeting persistent challenges in mechanical thrombectomy, Anaconda aims to improve outcomes for stroke patients worldwide.